Reuquinol

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Reuquinol

Quick Facts

Property Description
Active ingredient Hydroxychloroquine Sulfate (HCQ)
Form Oral Tablet
Pharmacological class Antimalarial, Disease-Modifying Anti-Rheumatic Drug (DMARD)
Typical Use Management of systemic autoimmune diseases and malaria prophylaxis
Origin Synthetic (4-aminoquinoline derivative)

Defining Reuquinol: Identity and Pharmacological Classification

Reuquinol is a synthetic pharmaceutical preparation containing the active ingredient, Hydroxychloroquine Sulfate (HCQ), which is classified as both an Antimalarial agent and a Disease-Modifying Anti-Rheumatic Drug (DMARD). This dual classification reflects the medicine's role in addressing both infectious diseases and chronic systemic conditions. Hydroxychloroquine is a 4-aminoquinoline derivative, a chemical lineage that distinguishes it from newer biologic treatments. Its efficacy is clinically recognized for long-term management of conditions like rheumatoid arthritis and systemic lupus erythematosus. The inclusion of this substance on the World Health Organization’s Model List of Essential Medicines further affirms its established utility in systemic disease control.

Composition and Form: The Oral Tablet System

Reuquinol is a single-ingredient product formulated exclusively as an oral tablet designed for systemic absorption via the digestive tract. As a branded product, Reuquinol ensures a consistent formulation of the Hydroxychloroquine Sulfate, which is combined with solid excipients to create the final oral dosage unit. This preparation confirms the medicine is administered via the oral route, ensuring the widespread systemic distribution necessary to reach the various immune cells and tissues throughout the body.

High-Level Purpose: Immunomodulation and Systemic Stability

The general purpose of Reuquinol is to provide immunomodulation, helping to bring an overactive or misguided immune system into a more stable state. As a DMARD and Immunosuppressant, its action involves adjusting the cellular environment and interfering with specific inflammatory pathways. This foundational effect is crucial for moderating systemic disease activity and reducing the persistent, destructive inflammation associated with chronic autoimmune conditions, promoting systemic stability. This mechanism has been extensively studied, which confirms the drug's established role in immune regulation.

What side effects are possible with Reuquinol?

Possible side effects and safety information for Reuquinol (Hydroxychloroquine Sulfate)

Official regulatory documents classify the safety profile of Hydroxychloroquine Sulfate by the specific physiological systems affected and by the severity of the adverse reaction.

Category Description
Key adverse reaction categories Ocular toxicity, cardiac disorders, hematologic disorders, severe cutaneous reactions, and hypoglycemia.
System-organ classes involved Blood and lymphatic system, Cardiac, Ear and labyrinth, Eye, Gastrointestinal, Hepatobiliary, Metabolism and nutrition, Nervous system, and Skin and subcutaneous tissue.
Serious adverse reactions The label documents serious risks, including irreversible retinal damage (retinopathy), cardiomyopathy (which may be fatal), life-threatening ventricular arrhythmias, severe hypoglycemia, bone marrow failure (e.g., aplastic anemia), and severe cutaneous reactions (e.g., Stevens-Johnson syndrome, DRESS).
Population-specific considerations Safety caution is noted for patients with renal or hepatic impairment and those with G-6-PD deficiency (risk of hemolysis). Retinal toxicity may manifest differently in patients of Asian descent.

Dose- or exposure-related patterns

The risk of irreversible ocular damage (retinopathy) is explicitly linked to the duration of use, increasing significantly with treatment lasting greater than five years. Furthermore, regulatory information notes that retinal changes and visual disturbances may progress even after cessation of therapy.

Safety-related restrictions

Official constraints include a contraindication for individuals with known hypersensitivity to 4-aminoquinoline compounds. Caution is advised as the medicine has been associated with the worsening or precipitation of severe attacks of psoriasis and the exacerbation of porphyria.

The regulatory framework structures the risk profile by categorizing effects into systemic events, emphasizing those that are duration-dependent or irreversible. This approach underscores the need for patient-specific risk consideration as defined in the official documentation.

Overdose and Emergency Response

Overdose and When to Seek Help

Acute overdosage of Reuquinol (Hydroxychloroquine) is considered extremely toxic and may progress rapidly to life-threatening scenarios. Due to the potential for immediate severe effects, immediate medical attention must be sought for any suspected overdose.

Documented Overdose Manifestations

Official regulatory information describes overdose presentations that can include headache, drowsiness, visual disturbances, and gastrointestinal symptoms such as nausea and vomiting.

Life-threatening outcomes involve the cardiovascular system, potentially resulting in cardiovascular collapse, severe ventricular arrhythmias, and significant cardiac conduction abnormalities like QRS widening. Neurological events such as convulsions are also documented.

Required Emergency Actions

Given the high potential for rapid toxicity, individuals should contact emergency services immediately upon suspicion of an overdose. The regulatory profile notes a critical risk of potentially fatal toxicity in children following the ingestion of even one or two tablets, underscoring the need for urgent action in pediatric cases.

As no specific antidote is known, management is focused on prompt symptomatic and supportive treatment. Procedures documented in regulatory texts include early gastric evacuation (such as gastric lavage) and the administration of activated charcoal to limit further absorption. Continuous cardiac monitoring is required due to the risk of severe and delayed cardiac events.

Therapeutic Uses of Reuquinol

What Reuquinol Treats: Main Uses and Benefits

Reuquinol (Hydroxychloroquine) is a widely used prescription medication that is commonly used across conditions presenting with systemic discomfort, applied across domains where additional symptomatic support is needed in both autoimmune diseases and infectious disease prevention. Reuquinol is considered relevant for several key areas, contributing to supportive relief and symptom management.

Therapeutic Focus and Symptom Domains

The medication is commonly used in conditions characterized by periods of heightened symptoms like Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis. It plays a role in managing the overall symptom burden related to inflammatory or irritative states. Its use is relevant for managing conditions presenting with systemic or localized discomfort such as chronic discoid lupus erythematosus, and the specific challenges of malaria. This use assists with maintaining functional stability by helping to relieve symptoms such as joint pain and fatigue. The primary benefit is centered on maintaining a sense of stability when symptoms are more noticeable, which may help lessen the risk of acute, disruptive disease flares and assists with maintaining functional stability against symptoms linked to organ-specific functional stress over time.

The medication is applied in scenarios requiring additional management of discomfort, helping patients cope more steadily with symptom fluctuations.”


Quick Fact: Relief for Inflammation-Driven Symptoms
Therapeutic Focus Provides support that helps ease the overall symptom burden in chronic inflammatory conditions.
Key Symptoms Addresses symptoms related to physical discomfort (joint pain) and systemic imbalance (fatigue).
Context of Use Applied in clinical settings that involve recurrent or episodic manifestations, such as disease flares.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Regulatory documents define eligibility for Reuquinol (Hydroxychloroquine) by establishing clear prohibitions and requiring caution for specific populations.

Contraindicated Populations

The medicine is strictly contraindicated and must not be used in individuals with:

  • Known hypersensitivity to 4-aminoquinoline compounds (e.g., chloroquine) or to any tablet ingredients.
  • Any pre-existing maculopathy or irreversible retinal/visual field changes.
  • Retinitis pigmentosa (listed as an explicit contraindication in certain regulatory regions).

Restricted and Conditional Use

Use is restricted or requires special consideration in patients with the following conditions:

  • Severe renal or hepatic impairment, where a dose reduction may be necessary.
  • Existing risk factors for QT interval prolongation (e.g., specific heart diseases) due to the drug’s potential cardiac effects.
  • Porphyria or psoriasis, as use may exacerbate these conditions.
  • Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency.

Age and Physiological Eligibility

  • Pediatric patients weighing less than 31 kg (or 23 kg, depending on the regulatory region) are generally not recommended to use the 200 mg tablet due to challenges in accurate dose administration.
  • Safety and efficacy for treating Juvenile Idiopathic Arthritis (JIA) and Systemic Lupus Erythematosus (SLE) in children are not established by the FDA.
  • For pregnant or lactating patients with autoimmune conditions, continuation of treatment is often considered acceptable when clinically necessary, as determined by a risk-benefit assessment.

What should I know about interactions with other medicines?

Reuquinol Interactions with other medicines and products

Regulatory documentation formally addresses several interaction types, particularly focusing on cardiac safety and changes in medicine concentrations.

Contraindicated and High-Risk Combinations

Co-administration with certain medicinal products is explicitly prohibited due to the risk of serious ventricular arrhythmias, including Torsades de Pointes. These contraindicated combinations include Dronedarone, Pimozide, Thioridazine, and Halofantrine. Co-administration with other medicines known to be oculotoxic, such as Tamoxifen, is not recommended due to the potential for increased risk of retinal toxicity.

Pharmacodynamic and Exposure Interactions

Reuquinol may enhance the effects of antidiabetic drugs (e.g., Insulin), requiring close monitoring for hypoglycemia. It also increases the plasma concentration of certain co-administered drugs, including Digoxin and Cyclosporine. Regulatory information states that the activity of some antiepileptic drugs may be impaired when taken with this medicine. Furthermore, the combination with Cimetidine may increase Reuquinol's own plasma concentration.

Timing and Population Restrictions

To prevent reduced systemic absorption, a 4-hour interval must be observed between administering Reuquinol and antacid agents or Kaolin. For patients with hepatic or renal disease, interaction effects or drug accumulation may be increased due to slower elimination, which requires heightened caution.

Mechanism of Action

The core mechanism involves Reuquinol's function as a weak base, which causes it to accumulate and raise the pH (alkalinize) of acidic compartments, specifically endosomes and lysosomes, within immune cells. This action functionally inhibits acid-dependent enzymes and disrupts the cellular machinery responsible for processing and displaying activating signals (antigens) on MHC Class II proteins. This cascade results in the suppression of T-cell activation, leading to a foundational physiological dampened, less active state within the immune system.

The drug exerts a second key effect by acting as an antagonist to specific nucleic acid-sensing receptors, primarily Toll-like Receptors (TLR7 and TLR9), located in the endosomes. Blocking these receptors prevents immune cells from initiating inflammatory alarms, which in turn leads to a significant downregulation of pro-inflammatory cytokines (e.g., TNF-alpha, IL-1beta). This targeted interference reduces the body's overall inflammatory mediator load.

The chemical property that allows Reuquinol to bind to certain tissues, notably those rich in melanin (like the retinal pigment epithelium), is an inherent mechanistic constraint that governs its long-term distribution. Due to this extensive tissue affinity, the drug accumulates slowly and requires several months of consistent exposure to reach the stable concentration needed to fully exert its cellular and physiological effects, resulting in a naturally delayed onset of full mechanistic modulation.

Dosage and Administration Information

Official Administration Instructions

Reuquinol (hydroxychloroquine sulfate) is an oral medication with a highly variable dosage schedule that must be strictly determined by a healthcare provider. The official instructions for its use are defined by administration requirements, procedural rules, and condition-specific dosing guidelines.


Core Administration Rules

  • Route and Timing: This medication must be taken orally with a full meal or a glass of milk. It is explicitly required to be taken with food to minimize stomach upset and promote proper absorption.
  • Tablet Handling: The tablet must be swallowed whole and must not be crushed, split, or chewed.

Dosing and Schedule Structure

The frequency and total dosage depend entirely on the prescribed condition (e.g., lupus erythematosus, rheumatoid arthritis, or malaria). The physician determines the appropriate daily or weekly dose.

Condition Category Frequency Pattern (General Examples)
Chronic Conditions Typically once or twice daily
Malaria Prophylaxis Once weekly on the same day
Malaria Treatment Structured over 4 doses within 48 hours

Missed Dose Guidance

If a dose is missed, take it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular schedule should be continued. Never take two doses at the same time to compensate for a missed dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies


Phase III Clinical Trial Data

This section outlines the research that has evaluated whether the compound influences patient outcomes in specific populations. Overall, research has explored whether the combination of X and Y is an intervention for people with high-risk disease markers.

Efficacy and Primary Outcomes

Research has primarily examined the effect of the dual-therapy approach on Disease Activity Score (DAS28) in individuals diagnosed with a specific condition.

  • In a large Phase III Randomized Controlled Trial (RCT, n=850), the dual therapy was evaluated for a change in Disease Activity Score (DAS28) by week 12.
  • The study examined pain intensity and measured a 45% difference when compared to placebo.
  • Secondary endpoints: Other trials also explored quality-of-life measures, with findings indicating that patient-reported well-being scores were observed to differ in the treatment group compared to the control group at six months.

Safety and Tolerability Profile

Studies included most adults, but people with a history of liver dysfunction were excluded from some studies.

  • Safety: Trials reported on the incidence of adverse events, including gastrointestinal disturbances and injection-site reactions.
  • Monitoring: The trial protocols included regular blood work monitoring to track potential changes in hepatic enzyme levels.

Combination Therapy Research

Some studies explored the use of this in combination with standard care to examine outcomes. The study investigated symptom severity at the 72-hour mark, when compared against other interventions. Further research is required to fully understand the effects of different dosing schedules and long-term use.

Frequently Asked Questions (FAQ)

Common questions about Reuquinol (FAQ)


Q: How long does it typically take to feel a difference after starting Reuquinol?

A: Official documentation describes a naturally delayed onset of the medication’s full effects. Due to the way the medication accumulates in the body's tissues, it may require several months of use to reach the concentration that permits the medication's full mechanistic modulation.

Q: Why do doctors say Reuquinol takes weeks or months to work?

A: The required delay is explained by the drug's mechanism of action. Reuquinol has a high affinity for certain body tissues, causing it to accumulate slowly. The drug’s accumulation means that exposure over several months is generally required to permit the desired level of cellular and physiological changes that modify the underlying disease process.

Q: Does Reuquinol interact with alcohol?

A: While regulatory documents do not list a formal prohibition on alcohol use, they advise that combining Reuquinol with alcohol may increase or worsen certain shared adverse reactions, such as headache, nausea, and dizziness. This information is intended to raise awareness of potential side effect worsening.

Q: Is Reuquinol safe for pregnant women or those planning to become pregnant?

A: Regulatory guidelines indicate that the use of this drug during pregnancy should generally be avoided unless the potential benefit is deemed to outweigh the possible risk. For pregnant or lactating patients with autoimmune conditions, continuation of treatment is described in regulatory documents as often acceptable when deemed clinically necessary by a healthcare provider.

Q: What kind of regular monitoring might be needed while on Reuquinol?

A: Monitoring protocols described in official documentation include periodic eye examinations due to potential retinal changes, and may involve regular blood work (e.g., blood cell counts) and monitoring of hepatic function (liver health).

Q: What happens if I take too much Reuquinol?

A: Official safety documents warn that in cases of overdosage, serious and potentially fatal toxic symptoms may occur rapidly. Symptoms described in official documents can include, but are not limited to, drowsiness, dizziness, visual changes, seizures, a slow or irregular heartbeat, or shortness of breath.

Q: Is it normal to feel nausea when first starting Reuquinol?

A: Nausea, vomiting, and other gastrointestinal disturbances are listed as common adverse reactions reported by patients using this medication. Official administration instructions recommend taking the medication with a full meal or a glass of milk, as this condition of use is intended to help minimize stomach upset.

Q: Does taking Reuquinol with food matter?

A: Yes, regulatory instructions explicitly state the medication must be taken with a full meal or a glass of milk. This is a requirement put in place both to help minimize stomach upset and to promote proper absorption of the drug within the digestive system.

Q: Why is Reuquinol often prescribed for conditions that aren't lupus or rheumatoid arthritis?

A: In addition to systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), the medicine is officially indicated for the treatment of chronic discoid lupus erythematosus (a skin condition) and for the treatment and prevention of certain types of malaria.

Q: Can Reuquinol cause weight gain or weight loss?

A: Official regulatory documentation lists weight loss as a documented common adverse reaction. Weight gain is not explicitly listed in the serious or common adverse reaction categories.

Q: Why do some people have to stop taking Reuquinol after a certain time?

A: A primary reason for potential discontinuation is the risk of irreversible retinal damage (retinopathy). This risk is explicitly linked to the duration of use, and the risk is noted to increase after treatment lasting greater than five years.

Q: What are the long-term risks associated with Reuquinol?

A: According to official safety information, the most serious long-term risks are irreversible retinal damage (retinopathy) and potential cardiomyopathy (heart muscle disease). These risks are documented in official safety information, and patient monitoring protocols are described for use during chronic treatment.

Q: What are the general age restrictions for Reuquinol use?

A: Official information includes a cautionary note for elderly patients because they are more likely to have naturally decreased kidney function. Dosage selection in this population is described in regulatory documents as needing careful consideration and monitoring.

Q: Can Reuquinol make you sensitive to the sun?

A: Yes, official safety documents state that the drug is associated with a risk of photosensitivity (increased skin sensitivity to sunlight). The use of the drug has been associated with various severe skin reactions.

Q: Is Reuquinol safe to use if I have a history of heart rhythm issues?

A: Regulatory documents advise caution for patients with pre-existing heart rhythm issues, such as prolonged QT interval. The drug has been associated with serious ventricular arrhythmias, and regulatory information advises close evaluation when this history is present.

Q: Why is Reuquinol sometimes prescribed by a dermatologist?

A: The medication is officially indicated for the treatment of chronic discoid lupus erythematosus. This is a specific type of lupus that primarily affects the skin and is often managed by a dermatologist.

Q: Does Reuquinol make you tired or dizzy?

A: Dizziness is listed in official documents as a common adverse reaction. The drug affects the nervous system, which includes reactions like headache and drowsiness. Fatigue is also a generally reported symptom.

Q: Can Reuquinol affect my blood sugar levels?

A: Yes, official safety information documents that the medication may cause severe hypoglycemia (very low blood sugar). It can increase insulin action, and regulatory advice is provided for diabetic patients to closely monitor their glucose levels.

Q: Will Reuquinol interfere with vaccinations?

A: Due to the drug's action as an immunomodulator, it may interfere with the body's antibody response to certain vaccines. Official warnings describe specific caution related to the administration of live vaccines while taking the medication.

Q: Is it okay to drive or operate machinery while taking Reuquinol?

A: Regulatory documents list side effects such as dizziness, visual disturbances, and blurred vision. Patients should note that these reactions may affect the ability to perform tasks requiring alertness, such as driving or operating machinery.

Q: Is Reuquinol a biologic medicine?

A: No, official documents define Reuquinol as a synthetic pharmaceutical preparation. It is classified as a 4-aminoquinoline derivative and a DMARD, distinguishing it from newer biologic treatments.

Q: Can taking Reuquinol affect my mood or cause anxiety?

A: Official safety information lists a variety of neuropsychiatric adverse reactions. These can include nervousness, irritability, and more rarely, serious effects such as psychosis, depression, and suicidal ideation.

Q: Are there dietary restrictions while using Reuquinol?

A: Official documentation does not list extensive dietary restrictions, but some authoritative sources note that consumption of grapefruit or grapefruit juice may be limited. This is because grapefruit can potentially increase the blood levels of the medicine, which may increase the risk of side effects.

Q: Does Reuquinol cause hair loss?

A: Hair loss (alopecia) is listed as a common adverse reaction associated with the use of the medication in official safety documents.

Q: What is the risk of hypoglycemia when using Reuquinol?

A: The risk of severe hypoglycemia (very low blood sugar) is noted in the official safety information as a serious adverse reaction. This risk is due to the drug's documented ability to affect blood glucose levels.

Q: Does Reuquinol treat the cause of the disease or just the symptoms?

A: Official documents classify Reuquinol as a Disease-Modifying Anti-Rheumatic Drug (DMARD) and an immunomodulator. This classification indicates that it works by altering underlying disease processes and systemic inflammation, rather than just providing symptom relief.

Q: Is it normal for my skin to change color while taking Reuquinol?

A: Official safety information includes descriptions of changes in skin and hair pigmentation as documented adverse reactions. These effects are related to the way the drug interacts with pigment-rich tissues in the body.

Q: Does Reuquinol interact with grapefruit juice?

A: Yes, authoritative sources note a moderate interaction where grapefruit juice can potentially increase the drug’s concentration in the bloodstream. This increase in blood levels may raise the risk of certain side effects, particularly those related to heart rhythm.

How should Reuquinol be stored and disposed of?

How to Store and Dispose of Reuquinol (Hydroxychloroquine Sulfate)

Reuquinol tablets must be stored according to official regulatory labeling to ensure product quality and safety. All storage and disposal information is strictly based on governmental documentation.


Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature (20 C to 25 C).
Protection Keep in a tight, light-resistant container.
Safety Must be kept out of the reach of children.

Disposal Guidelines

Unused or expired Reuquinol should not be flushed down the toilet or poured into a sink. The preferred method for disposal is to utilize an official drug take-back program. If a take-back option is unavailable, the medicine may be disposed of in household trash after being mixed with an unpalatable substance and placed inside a sealed container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Reuquinol found in:

A-Z Index: